597561-78-9

Basic information

• Product Name: 4-(OXAZOL-2-YL)BENZOIC ACID
• Synonyms: 4-(OXAZOL-2-YL)BENZOIC ACID
• CAS NO: 597561-78-9
• Molecular Formula: C₁₀H₇NO₃
• Molecular Weight: 189.17
• Mol File: 597561-78-9.mol

Chemical Properties

• Boiling Point: 375.8±44.0 °C(Predicted)
• Appearance: /
• Density: 1.320±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.87±0.10(Predicted)
• CAS DataBase Reference: 4-(OXAZOL-2-YL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(OXAZOL-2-YL)BENZOIC ACID(597561-78-9)
• EPA Substance Registry System: 4-(OXAZOL-2-YL)BENZOIC ACID(597561-78-9)

Safety Data

• Hazardous Substances Data: 597561-78-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(OXAZOL-2-YL)BENZOIC ACID is used as a key building block for the creation of pharmaceuticals, leveraging its structural properties to contribute to the development of new drugs.
Used in Organic Compounds Synthesis:
In the realm of organic chemistry, 4-(OXAZOL-2-YL)BENZOIC ACID is utilized as a component in the synthesis of a variety of organic compounds, enhancing the diversity and complexity of chemical libraries.
Used as a Reagent in Chemical Reactions:
4-(OXAZOL-2-YL)BENZOIC ACID is employed as a reagent, facilitating specific chemical transformations and reactions that are essential in the advancement of chemical research and development.
Used in Material Development:
4-(OXAZOL-2-YL)BENZOIC ACID is also used in the development of new materials, where its unique properties can contribute to the creation of innovative and improved materials for various applications.
Used in Medicinal Chemistry Research:
4-(OXAZOL-2-YL)BENZOIC ACID is used as a subject of study in medicinal chemistry, where its potential biological activity is explored for future applications in drug development.
Used in Drug Development:
With its potential biological activity, 4-(OXAZOL-2-YL)BENZOIC ACID is of interest for further investigation in drug development, where it may lead to the discovery of new therapeutic agents.

Upstream product

• 1679-64-7 Monomethyl terephthalate 
• 421553-40-4 methyl 4-(oxazol-2-yl)benzoate 
• 861103-21-1 N-(2,2-dimethoxy-ethyl)-terephthalamic acid methyl ester 
• 619-66-9 4-Carboxybenzaldehyde 
• 619-65-8 4-cyanobenzoic Acid 
• 6051-43-0 terephthalamic acid 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 

Downstream Products

• 1404449-48-4 ethyl 3-(4-(oxazol-2-yl)phenyl)-3-oxopropanoate 

Relevant articles and documents

Ring size changes in the development of class I HDAC inhibitors

Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.

Synthesis method of 4-(oxazol-2-yl)benzoic acid

The invention relates to a synthesis method of 4-(oxazol-2-yl)benzoic acid. Ethanolamine and 4-carboxybenzaldehyde are used as starting materials, firstly 4-(4,5-dihydroxazol-2-yl)benzoic acid is synthesized, then N-bromosuccinimide and azodiisobutyronitr

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY

The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.